InsidersTradesSigma
Total declarations
Companies
▲ Purchases (53 ops.)
▼ Sales (22 ops.)
Insider track record
CEODisclosed buys
53
Disclosed sells
22
T+90 hit rate
35%
T+90 mean return
+80.3%
Across 20 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by Perceptive Advisors Llc, Managing Member / Founder and CEO. Insider active across 28 companies, notably Aldeyra Therapeutics, Inc.. Cumulatively, 88 reports have been published. Breakdown: 53 buys · 22 sells. Total volume traded: €309.2m. Activity tracked since 3 May 2021. The latest transaction was disclosed on 26 August 2026 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Perceptive Advisors Llc
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations88 total
863,060 shares@ US$8.69Ordinary SharesSEC:0001193125-26-371237:0
Canonical exit: 24 Nov 2026 (T+90)
5,500,000 shares@ US$10.00100.0% of flowCommon StockSEC:0001193125-26-312798:0
20,706 shares0Common StockSEC:0001193125-26-302095:0
555,555 shares@ US$9.000.36% mcap13.5% of flowOrdinary SharesSEC:0001193125-26-174407:0
2,300,000 shares@ US$7.9133.0% of flowOrdinary SharesSEC:0001193125-26-000939:0
989,270 shares@ US$6.3567.1% of flowCommon StockSEC:0001012975-25-000979:0
329,756 shares@ US$6.3522.4% of flowCommon StockSEC:0001012975-25-000979:1
4,783 shares@ US$4.314612.1% of flowCommon StockSEC:0001193125-25-280481:0
28,902 shares@ US$5.1799100.0% of flowCommon StockSEC:0001193125-25-274540:0
700,000 shares@ US$2.75100.0% of flowCommon StockSEC:0000950170-25-102537:0
Canonical exit: 30 Oct 2025 (T+90)
437,881 shares@ US$1.412.5% of flowCommon StockSEC:0001062993-25-008341:0
215,283 shares@ US$1.561.4% of flowCommon StockSEC:0001062993-25-008214:1
250,000 shares@ US$1.411.4% of flowCommon StockSEC:0001062993-25-008214:2
1,054,669 shares@ US$1.958.4% of flowCommon StockSEC:0001062993-25-008214:0
3,400,000 shares@ US$1.4210.5% of flowCommon StockSEC:0001062993-25-007163:0
5,000,000 shares@ US$4.0337.8% of flowCommon StockSEC:0001062993-25-003153:0
Canonical exit: 20 May 2025 (T+90)
64,167 sharesCommon StockSEC:0001062993-25-002547:0
1,250,000 shares@ US$4.0016.8% of flowOrdinary SharesSEC:0001062993-24-015109:0
Canonical exit: 10 Nov 2024 (T+90)
2,353,000 shares@ US$8.5086.3% of flowCommon StockSEC:0001062993-24-008378:0
Canonical exit: 10 Jul 2024 (T+90)
140,281 shares@ US$4.671.4% of flowCommon StockSEC:0001062993-24-008171:0
Canonical exit: 3 Jul 2024 (T+90)
8,374 shares@ US$3.250.1% of flowCommon StockSEC:0001062993-24-007959:0
Canonical exit: 30 Jun 2024 (T+90)
170,317 shares0Common StockSEC:0001062993-24-003957:0
36,300 shares@ US$2.520.1% of flowOrdinary SharesSEC:0001062993-24-003732:0
2,481,350 shares@ US$12.0961.4% of flowCommon StockSEC:0001062993-24-001979:0
Canonical exit: 1 May 2024 (T+90)
3,410,713 shares@ US$5.5333.7% of flowCommon StockSEC:0001062993-24-000843:0
Canonical exit: 10 Apr 2024 (T+90)
25 of 88 declarations
About Perceptive Advisors Llc
PERCEPTIVE ADVISORS LLC is a managing member / founder and CEO. The entity has filed 85 disclosures in total, and in the recent filings available, buy volume in euros is 271475953 and sell volume is 46736781, over the period from 2021-05-04 to 2026-04-23. It is linked to Aldeyra Therapeutics, Inc., Cerevel Therapeutics Holdings, Inc. as Director, LianBio as Director, Acrivon Therapeutics, Inc., Soleno Therapeutics INC and MeiraGTx Holdings plc as Director.
